<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109111">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01699464</url>
  </required_header>
  <id_info>
    <org_study_id>AR-12286-CS206</org_study_id>
    <nct_id>NCT01699464</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months</brief_title>
  <official_title>Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerie Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerie Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-masked, parallel study of AR-12286 Ophthalmic Solution 0.5%, or 0.7% (q.d., PM) or
      timolol maleate Ophthalmic Solution, 0.5% (b.i.d.), O.U. for 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean IOP across subjects within treatment group at each post-treatment timepoint of Month 3</measure>
    <time_frame>Month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Intraocular pressure</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>AR-12286 Ophthalmic Solution 0.7%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AR-12286 Ophthalmic Solution 0.7%, both eyes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR-12286 Ophthalmic Solution 0.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AR-12286 Ophthalmic Solution 0.5% both eyes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol maleate ophthalmic solution 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Timolol maleate ophthalmic solution 0.5% both eyes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR-12286 Ophthalmic Solution 0.7%</intervention_name>
    <description>Ophthalmic Solution</description>
    <arm_group_label>AR-12286 Ophthalmic Solution 0.7%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR-12286 Ophthalmic Solution 0.5%</intervention_name>
    <description>Ophthalmic Solution</description>
    <arm_group_label>AR-12286 Ophthalmic Solution 0.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol maleate ophthalmic solution 0.5%</intervention_name>
    <description>Ophthalmic Solution</description>
    <arm_group_label>Timolol maleate ophthalmic solution 0.5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 year of age or greater.

          2. Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).

          3. Unmedicated (post-washout) IOP ≥ 24 mm Hg at 2 eligibility visits (0800 hr), 2-7 days
             apart, and ≥ 22 mm Hg at 1000 and 1600 hrs at the second qualification visit. If only
             one eye meets the IOP criteria it must be the same eye that met the criteria at all
             the qualification timepoints.

          4. Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye
             (equivalent to 20/200).

          5. Able and willing to give signed informed consent and follow study instructions.

        Exclusion Criteria:

        Ophthalmic

          1. Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure
             or narrow angles. Note: Previous laser peripheral iridotomy is NOT acceptable.

          2. IOP &gt; 36 mm Hg

          3. Current use of more than 1 ocular hypotensive medications (Note: fixed dose
             combinations are considered multiple medications).

          4. Known hypersensitivity to any component of the formulation (benzalkonium chloride,
             etc.), or to topical anesthetics.

          5. Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s).

          6. Refractive surgery in study eye(s) (e.g., radial keratotomy, PRK, LASIK, etc.).

          7. Ocular trauma within the past six months, or ocular surgery or laser treatment within
             the past three months.

          8. Evidence of ocular infection, inflammation, clinically significant blepharitis or
             conjunctivitis at baseline (Visit 1), or a history of herpes simplex keratitis

          9. Ocular medication of any kind within 30 days of Visit 1, with the exception of a)
             ocular hypotensive medications (which must be washed out according to the provided
             schedule), b) lid scrubs (which may be used prior to, but not after Visit 1) or c)
             lubricating drops for dry eye (which may be used throughout the study).

         10. Clinically significant ocular disease (e.g. uveitis, severe keratoconjunctivitis
             sicca) which might interfere with the study, including glaucomatous damage so severe
             that washout of ocular hypotensive medications for one month is not judged safe
             (i.e., cup-disc ratio &gt; 0.8).

         11. Central corneal thickness greater than 600 µm.

         12. Any abnormality preventing reliable applanation tonometry of either eye.

             Systemic:

             Systemic:

         13. Clinically significant abnormalities (as determined by the treating physician) in
             laboratory tests at screening.

         14. Known hypersensitivity or contraindication to beta adrenoceptor antagonists including
             chronic obstructive pulmonary disease or bronchial asthma; abnormally low blood
             pressure or heart rate; second or third degree heart block or congestive heart
             failure; severe diabetes).

         15. Clinically significant systemic disease (e.g., myasthenia gravis, hepatic, renal,
             endocrine or cardiovascular disorders) which might interfere with the study.

         16. Participation in any investigational study within the past 30 days.

         17. Changes of systemic medication that could have a substantial effect on IOP within 30
             days prior to screening, or anticipated during the study.

         18. Due to the current status of the preclinical safety program, women of childbearing
             potential who are pregnant, nursing, planning a pregnancy, or not using a medically
             acceptable form of birth control.  An adult woman is considered to be of childbearing
             potential unless she is one year post-menopausal or three months post-surgical
             sterilization.  All females of childbearing potential must have a negative urine
             pregnancy test result at the screening examination and must not intend to become
             pregnant during the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kenneth Sall, M.D.</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aesthetic Eye Care Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bacharach practice</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clayton Eye Center</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Research Associates, LLC</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradley Kwapiszeski, MD</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taustine Eye Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Ophthalmological Group</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye Ear Nose and Throat</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael E. Tepedino, M.D.</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texan Eye</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cataract &amp; Glaucoma Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Ophth. Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vittala International Institute of Ophthalmology</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narayana Nethralaya Super Speciality Eye Hospital</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Hospital</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Shroff's Charity Eye Hospital</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIIMS</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LVPEI</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMC</name>
      <address>
        <city>Ludhiana</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Institute</name>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Conwest and Manjula S Badani Jain Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Hospital</name>
      <address>
        <city>Tirunelveli</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>India</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>October 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
